ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2021
Clinical Implications of Minimal Residual Disease Detection in Infants With
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 62 citations in OpenAlex.
- Bortezomib and vorinostat in combination with mitoxantrone, dexamethasone, and pegasparaginase during induction and reinduction for infants with acute lymphoblastic leukaemia: a multicentre single-arm phase 1/2 study.The Lancet. Haematology · 2026Trial
- Azacitidine as epigenetic priming for chemotherapy is safe and well-tolerated in infants with newly diagnosedHaematologica · 2024Trial
- High-risk features in adult patients with B-cell acute lymphoblastic leukemia: redefining risk in the era of targeted immunotherapy.Blood research · 2026Review
- [KMT2A-rearranged acute lymphoblastic leukemia with lineage switch following relapse: a case report and literature review].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026Review
- From cell lines to PDXs: in vivo confirmation of synergistic drug responses identified in leukemia cell line models.Blood neoplasia · 2026Article
- Genomic fusion breakpoints for DNA-based measurable residual disease monitoring in pediatric acute lymphoblastic leukemia.Leukemia · 2026Article
- Successful Long-Term Remission in Infantile Acute Leukemia Treated With Chemotherapy and Blinatumomab: A Case Report.The American journal of case reports · 2026Article
- A characteristic gene expression profile regulated by ACIN1::NUTM1 fusion in a newly identified infant leukaemic cell line and an ACIN1::NUTM1-inducible model.British journal of haematology · 2025Article
- Prognostic value of dynamic minimal residual disease monitoring for adolescent and adult T-lymphoblastic leukemia/lymphoma.Annals of hematology · 2025Article
- Review
- Moving the Needle in KMT2A Rearranged Pediatric B-Cell Acute Lymphoblastic Leukemia: Newer agents and novel approaches.Clinical hematology international · 2025Review
- Minimal Residual Disease in Acute Lymphoblastic Leukaemia and Its Relationship with Other Prognostic Factors.International journal of hematology-oncology and stem cell research · 2025Article
- Review
- Measurable residual disease quantification in adult patients with KMT2A-rearranged acute lymphoblastic leukemia.Leukemia · 2024Article
- Genomic breakpoint-specific monitoring of measurable residual disease in pediatric non-standard-risk acute myeloid leukemia.Haematologica · 2024Article
- Review
- Advancing Diagnostics and Therapy to Reach Universal Cure in Childhood ALL.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Review
- Article
- Modelling acquired resistance to DOT1L inhibition exhibits the adaptive potential of KMT2A-rearranged acute lymphoblastic leukemia.Experimental hematology & oncology · 2023Article
- Minimal residual disease predicts outcomes in KMT2A-rearranged but not KMT2A-germline infant acute lymphoblastic leukemia: Report from Children's Oncology Group study AALL0631.Pediatric blood & cancer · 2023Article
Corrections and comments
- Erratum issued
Authors and funding
27 authors at 14 institutions in 11 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeInfant acute lymphoblastic leukemia (ALL) is characterized by a high incidence of MATERIALS AND
methodsMRD was measured in 249 infants by DNA-based polymerase chain reaction of rearranged
resultsEOI MRD levels predicted outcome with 6-year disease-free survival (DFS) of 60.2% (95% CI, 43.2 to 73.6), 45.0% (95% CI, 28.3 to 53.1), and 33.8% (95% CI, 23.8 to 44.1) for infants with negative, intermediate, and high EOI MRD levels, respectively (
conclusionThis study provides support for the idea that induction therapy selects patients for subsequent therapy; infants with high EOI MRD may benefit from AML-like consolidation (DFS 45.9%
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.